

**Name:** Lauren Brown

**Position & Affiliation:** PhD Candidate, Westmead Institute for Medical Research, University of Sydney; Medical Oncology Fellow Westmead and Blacktown Hospitals.

**Full Reference:** Patterns of response and progression with immune-checkpoint inhibitor combinations in advanced Non-small cell lung cancer (NSCLC). Lauren J Brown, Julie Ahn, Adnan Nagrial, Harriet Gee, Eric Hau and Ines Pires Da Silva

**Conference/Meeting Name:** Australian Lung Cancer Conference 2023

**Location:** Gold Coast, QLD, Australia

**Dates:** 14-17<sup>th</sup> February 2023

**Presentation Type :** Oral presentation



This is following my oral presentation. Feeling relieved. A picture of the beach I ran along every day.

The Australian Lung Cancer Conference (ALCC) was held in mid-February in the Gold Coast Queensland This is a multidisciplinary conference with oncologists, scientists, nursing staff, radiation oncologists and respiratory physicians to come together to discuss emerging research in lung cancer.

The invited speakers included Prof Ben Solomon from Peter MacCallum Cancer Centre in Melbourne who spoke about the new targeted therapies in lung cancer. Dr Renelle Myers from the University of British Columbia in Canada spoke of emerging experience of lung cancer screening in Canada and how that can be implemented in Australian settings.

There was certainly an overwhelming theme regarding multi-omics technologies to better understand the building blocks of lung cancer and ways in which to overcome therapeutic

resistance. The excitement around artificial intelligence technologies to analyse pathology samples and imaging for patients with lung cancer was also evident.

The discussions I had with people from across NSW and Australia have assisted in building new relationships with the possibility of collaborations across research centres in the future.

I hope to see how I can apply artificial intelligence and machine learning technologies to my own research in unlocking the site specific patterns of resistance to immunotherapy in Non-small cell lung cancer.

For the wider Sydney Cancer Partners membership, I think we can certainly expect to see an increase in research and technologies using artificial intelligence and machine learning to evaluate data and predict outcomes for patients.

The highlight of my trip was being able to run along the beach just in front of the conference centre everyday prior to the conference.